Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grid Dynamics Co-Hosts Physical AI Summit Alongside NVIDIA, EAIGG, and BGV to Accelerate Manufacturing Automation23.9.2026 23:05:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, announced today that it is co-hosting the Physical AI Summit alongside NVIDIA, EAIGG, and BGV. The invite-only working forum will bring together participants from enterprises, Physical AI startups, and investors on September 24, 2026, at the Wells Fargo Innovation Center in Menlo Park, CA. Centered on the theme "From World Models to Real-World Control," the summit will focus on the practical challenges of deploying, scaling, and operating Physical AI systems in production. Grid Dynamics' participation builds on its strategic partnerships with NVIDIA and Doosan Robotics, expanding its Physical AI capabilities to advance enterprise robotics applications. Ilya Katsov, CTO, Americas at Grid Dynamics, will lead a session titled "Operationalizing Physical AI: Lessons From the Field." The session will draw on Grid Dynamics' experience deploying Physical AI, including humano
Liquid AI, in Collaboration with Qualcomm Technologies, Brings Personal AI Context to Devices Powered by Snapdragon23.9.2026 22:00:00 EEST | Press release
Liquid AI today, at Snapdragon Summit 2026, announced that Liquid Context, an on-device context layer, is now optimized for Snapdragon® processors, specifically using the Qualcomm® Hexagon™ NPU. In collaboration with Qualcomm Technologies, Liquid Context built a persistent understanding of the user from signals from devices with Snapdragon processors and made relevant context available to AI agents, whether they ran on the device, in the cloud or across both. Device manufacturers now have a foundation for more proactive, personalized and trustworthy AI experiences, alongside Liquid Agent, Liquid AI’s efficient embedded agent. Personal Context That Makes Any Agent More Useful Useful agents need to understand what matters to the user and when help is needed. With the user’s permission, Liquid Context learns from device signals, builds an understanding of routines, preferences and needs, and keeps that understanding current. It provides a shared context layer between the device and the us
Doha Debates Podcast Returns for a New Season Exploring the Ideas Shaping Our World23.9.2026 20:29:00 EEST | Press release
Qatar Foundation’s Doha Debates has launched a new season of the Doha Debates Podcast, with 20 episodes airing weekly through February 16, 2027. The series brings leading global thinkers together to debate some of the world’s most complex and challenging issues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923050361/en/ Doha Debates Podcast Returns for a New Season (Photo: AETOSWire) The podcast carries forward themes from its flagship debates and town halls through long-form conversations, reflecting Doha Debates’ commitment to open, truth-seeking dialogue exploring global issues with depth, nuance and respect for diverse perspectives. The opening episode, “Will China or the West lead the world into the future?” moderated by Soraya Salam, brings together Renata Ávila, CEO of the Open Knowledge Foundation; Arnaud Bertrand, entrepreneur; Isabel Hilton, visiting professor at the Lau China Institute, King's College, London
Dryad Wins International XPRIZE Wildfire Award for Autonomous Wildfire Detection and Suppression23.9.2026 20:00:00 EEST | Press release
Dryad Networks, a leader in ultra-early wildfire detection, today announced it has been awarded $800,000 in the XPRIZE Wildfire competition for its performance in the Autonomous Wildfire Response finals in Alaska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923024178/en/ Silvaguard Observation and Suppression drone and Hangar Dryad advanced from an original field of approximately 300 entrants in the four-year competition. In June 2026, three finalists were challenged to autonomously detect and completely suppress a high-risk wildfire within 10 minutes of ignition across 1,000 km² of Alaskan wilderness, leaving any decoy fires untouched. It was the most demanding live test to date of what it will take to stop a destructive fire before it grows out of control. During the tests, the Dryad’s Silvanet sensor network successfully detected and verified target fire in 12 minutes or less and autonomously launched a response, ig
SES Appoints Michel Scholer to Board of Directors23.9.2026 19:54:00 EEST | Press release
SES today announced the appointment of Mr. Michel Scholer, Secretary General of the Luxembourg Government and Chief of Staff to the Prime Minister, to its Board of Directors effective immediately. This appointment is part of SES’s Board succession planning and ongoing commitment to regularly review and strengthen the composition of its Board with diverse expertise and industry experience, ensuring the company is well positioned for future growth and value creation. Prior to his current role with the Luxembourg Government, Mr. Scholer served as a Senior Adviser to the International Monetary Fund, and with the Ministry of Finance, Luxembourg. He was nominated for the SES Board of Directors by the Government of the Grandy Duchy of Luxembourg. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom